Tag Archives: genomics personalized medicine

No Summer Doldrums In Biotech Today … PBYI…Update-1

Update 7/23 Biogen Idec (BIIB) Soars 11% on Earnings EPS at $3.49 vs est $2.83; Sales of MS drugs were $2.42B vs $1.72B last year. Our large cap portfolio is now up 15% YTD with less risk than mid and small caps. One analyst thinks PBYI will be acquired but watch out with a market […]

Leave a comment Continue Reading →

Rayno Diagnostics and Tools Stocks: GHDX, ILMN, QGEN, RGDX.

Rayno Life Science Stocks Focused on Genetic Tests and Biomarkers We have been writing about molecular diagnostics and tools stocks for over 5 years. Here is the summary of our Portfolio. Yesterday we provided an update from BIO 2014  on personalized medicine and genetic tests. Many genetic tests are not FDA approved usually called LDTs […]

Comments Off Continue Reading →

BIO 2014 Update #1 Personalized Medicine-Megatrend Momentum Continues

Challenges Ahead But Sequencing Is  A Driver We first reported on Personalized Medicine in 2010 with an article on the importance of  Biomarkers for exploiting breakthroughs in the molecular basis of disease. The BIO 2014 Personalized Medicine and Diagnostics Forum provided full day coverage offering insights as to how the science driving personalized medicine is reshaping […]

Comments Off Continue Reading →

Rayno Dx and Tools 2014 YTD After Correction: ILMN, HOLX, RHHBY

April Sell-Off Hit Diagnostic Small and Mid Caps The bursting of the biotech bubble affected many small cap growth stocks. 2013 was a great year for our portfolio so some weakness was expected after the huge Q1 2014 moves. Most of our picks peaked in Jan/Feb time frame when many of our favorites were hit […]

Comments Off Continue Reading →

Pre-ASCO Watch List #2: ARIA, IMGN, PCYC

Rayno Life Science Focus Stocks: ARIA, IMGN, PCYC  Ariad (ARIA) Abstracts Several data presentations will be made for Iclusig (Ponatinib)  for leukemias and AP26113 its investigational oral inhibitor of anaplastic lymphoma kinase (ALK). A breakfast meeting featuring key investigators and slide presentations will be held on June 2. Immunogen (IMGN) Abstracts The focus will be on […]

Comments Off Continue Reading →

Risk Appetite Returns To Biotech With IBB Up Over 3%

Rayno Life Science Stocks -Green Screen Rules-NASDAQ (4168) Up 1.16% Speculative ETF XBI (134.50) up 4.69% and 7.88% over 5 days; 52 week high $172.52. ETF PBE ($40.85)  up over 3%. Momentum stocks are soaring but way off all time highs in February. Big Rayno Biopharma Movers: ACHN up 8%, ALKS up 3.4%, ARIA up […]

Comments Off Continue Reading →